Engineered immune cells take aim at tough leukemia
NCT ID NCT05672147
Summary
This early-stage study is testing the safety and best dose of a new cell therapy for adults with acute myeloid leukemia that has returned or hasn't responded to standard treatments. Doctors take immune cells (T-cells) from a donor, modify them in a lab to better target the leukemia, and infuse them back into the patient. The main goals are to see if the treatment is safe and to learn how well it might work against the cancer.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for REFRACTORY ACUTE MYELOID LEUKEMIA are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
City of Hope Medical Center
RECRUITINGDuarte, California, 91010, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Conditions
Explore the condition pages connected to this study.